Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) Ove... | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) Pr... | 10 | 1 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) P... | 11 | 1 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) P... | 12 | 2 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) P... | 14 | 2 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) P... | 16 | 4 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) P... | 20 | 2 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) T... | 22 | 5 |
| Assessment by Monotherapy/Combination Products | 22 | 1 |
| Assessment by Mechanism of Action | 23 | 1 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 1 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) C... | 27 | 12 |
| Astex Pharmaceuticals, Inc. | 27 | 1 |
| AstraZeneca Plc | 28 | 1 |
| Bayer AG | 29 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 30 | 1 |
| Eli Lilly and Company | 31 | 1 |
| Jyant Technologies, Inc. | 32 | 1 |
| Presage Biosciences, Inc. | 33 | 1 |
| Selvita S.A. | 34 | 1 |
| Tolero Pharmaceuticals, Inc. | 35 | 1 |
| Tragara Pharmaceuticals, Inc. | 36 | 1 |
| Vichem Chemie Research Ltd. | 37 | 1 |
| ViroStatics srl | 38 | 1 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) D... | 39 | 37 |
| alvocidib hydrochloride Drug Profile | 39 | 4 |
| alvocidib hydrochloride Drug Profile | 43 | 1 |
| AT-7519 Drug Profile | 44 | 3 |
| AZ-5576 Drug Profile | 47 | 1 |
| BAY-1112054 Drug Profile | 48 | 1 |
| CCT-68127 Drug Profile | 49 | 1 |
| CYC-065 Drug Profile | 50 | 3 |
| FIT-039 Drug Profile | 53 | 1 |
| LY-2857785 Drug Profile | 54 | 1 |
| sapacitabine + seliciclib Drug Profile | 55 | 3 |
| SEL-120 Drug Profile | 58 | 2 |
| seliciclib Drug Profile | 60 | 2 |
| Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections Drug Profile | 62 | 1 |
| Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers Drug Profile | 63 | 1 |
| Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections Drug Profile | 64 | 1 |
| Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology Drug Profile | 65 | 1 |
| Small Molecule to Inhibit CDK9 for Multiple Myeloma Drug Profile | 66 | 1 |
| Small Molecule to Inhibit Cyclin Dependent Kinase 9 for Oncology Drug Profile | 67 | 1 |
| Small Molecules to Inhibit CDK9 for HIV-1 Infection Drug Profile | 68 | 1 |
| Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis Drug Profile | 69 | 1 |
| TG-02 Drug Profile | 70 | 3 |
| TP-1287 Drug Profile | 73 | 1 |
| voruciclib Drug Profile | 74 | 2 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) D... | 76 | 2 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) D... | 78 | 1 |
| Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) F... | 79 | 12 |
| Jun 13, 2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due to the Targeting of MCL-1 | 79 | 1 |
| Jun 06, 2016: Tolero Pharmaceuticals To Present Update On Alvocidib Program At 2016 EHA Congress | 79 | 1 |
| Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO | 80 | 2 |
| Jun 06, 2016: Tolero Pharmaceuticals To Present Update On TP-1287 Program At 2016 EHA Congress | 82 | 1 |
| Jun 03, 2016: Presage Biosciences Appoints David Johnson to Board of Directors | 82 | 1 |
| May 19, 2016: Cyclacel s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting | 83 | 1 |
| Apr 20, 2016: Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Multiple Drug Combination Strategies Due to the Targeting of MCL-1 | 83 | 1 |
| Apr 19, 2016: Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer | 84 | 1 |
| Apr 18, 2016: Cyclacel s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors | 85 | 1 |
| Apr 12, 2016: Tolero Pharmaceuticals to Present Update on Alvocidib at the AACR Annual Meeting 2016 | 86 | 1 |
| Dec 14, 2015: Molecular Basis for Development of Cyclacel s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium | 87 | 1 |
| Dec 08, 2015: Tolero Pharmaceuticals Announces Mechanistic Data Describing the Activity of Alvocidib within a Time-sequential Regimen | 87 | 1 |
| Dec 07, 2015: Tolero Pharmaceuticals Presents Preclinical Data Demonstrating Synergistic Activity with a Combination of Alvocidib and Azacytidine | 88 | 1 |
| Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models | 89 | 1 |
| Nov 12, 2015: Tolero Pharmaceuticals Presents Positive Clinical and Preclinical Data on alvocidib at the 57th ASH Annual Meeting and Exposition | 90 | 1 |
| Appendix | 91 | 2 |
| Methodology | 91 | 1 |
| Coverage | 91 | 1 |
| Secondary Research | 91 | 1 |
| Primary Research | 91 | 1 |
| Expert Panel Validation | 91 | 1 |
| Contact Us | 91 | 1 |
| Disclaimer | 92 | 1 |